AAV Curator™ Platform
A proven foundation for delivering high-quality lentiviral vectors through an integrated lentiviral CDMO model.
Our lentiviral vector CDMO approach aligns development and manufacturing to streamline outcomes.
Highlights of the LVV Curator® Platform
Built on the Curator® Platform, which has supported more than 100 AAV programs and provides a framework that minimizes development risk and informs lentiviral manufacturing. This experience now underpins our lentiviral vector CDMO offering.
Uses a clinically validated Curator® HEK293 cell line with established regulatory acceptance, helping streamline development and build regulatory confidence in a lentivirus CDMO engagement.
Collaborative development begins at project initiation, with DOE and data-driven optimization to establish robust processes more quickly across lentiviral production services.
Extends a commercially validated platform approach to lentiviral vector manufacturing, bringing consistency, scalability, and operational discipline to early-stage LVV programs and to the broader lentiviral CDMO offering.
Processes are designed with GMP requirements in mind from the outset and supported by unified cGMP quality systems aligned with commercial lentiviral manufacturing standards.
Configurable modules adapt to program needs while maintaining standardized controls for predictable performance within a lentiviral vector CDMO framework and across our lentiviral production services.
LVV Curator® Platform Process
Optimization-By-Design™
Industrializing gene therapy processes with a reductionist, holistic, and systematic optimization methodology
Consistency in productivity and quality are evaluated at each stage of development and measured with enabling technologies.
Benefits of Our Platform Approach
Reduced Spending on Optimization
High Productivity and % Full Capsids driving production costs down
No MCB Generation Costs
No Tech Transfer Costs
No PreClinical/clinical Licensing Fees
Reduced time spent on opTimization
Off the Shelf (OTS) plasmids readily avaIlable
No MCB generatIon time
Supply Chain Already Established
NO TECH TRANSFER/DOCUMENTATION TIME
DMFs filed for Andelyn’s platform
Same equipment in non-GMP & GMP
Same quality systems
Integrated teams in Preclinical & Clinical